With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T cell immunity is protective against recurrence of both breast and ovarian cancer. Based on pre-existent immunity, several degenerate epitope-based vaccines have been developed targeting tumor-associated antigens such as HER2/neu and the Folate Receptor Alpha. These vaccines demonstrate the ability to generate robust long-lived immunity and may have a role, when combined with other agents, in protecting against disease relapse.
1. Learn fundamentals of vaccination
2. Learn types of antigens that are targeted with cancer vaccines.
3. Learn clinical settings in which vaccines are being used.